Two cases of visceral leishmaniasis in Colombia resistant to meglumine antimonial treatment

Revista do Instituto de Medicina Tropical de Sao Paulo

Volumn 51, Issue 4, 2009, Pages 231-236

  Vélez, Iván Darío ^a   Colmenares, Lina María ^a   Muñoz, Carlos Aguirre ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

Liposomal amphotericin B; Pentavalent antimonial; Therapeutic failure; Visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; MEGLUMINE ANTIMONATE; STIBOGLUCONATE SODIUM;

ANAMNESIS; ARTICLE; BLOOD ANALYSIS; CASE REPORT; CENTRAL AMERICA; CHILD; CLINICAL FEATURE; COLOMBIA; FEMALE; HUMAN; LEISHMANIA INFANTUM; MALE; NONHUMAN; PRESCHOOL CHILD; TREATMENT FAILURE; VISCERAL LEISHMANIASIS;

ADOLESCENT; ANIMALS; ANTIPROTOZOAL AGENTS; CHILD, PRESCHOOL; COLOMBIA; DRUG RESISTANCE; ENDEMIC DISEASES; FEMALE; HUMANS; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; MALE; MEGLUMINE; ORGANOMETALLIC COMPOUNDS;

EID: 70349325669     PISSN: 00364665     EISSN: 16789946     Source Type: Journal    
DOI: 10.1590/S0036-46652009000400011     Document Type: Article

References (32)

1. ASHUTOSH; SUNDAR, S. & GOYAL, N. - Molecular mechanisms of antimony resistance in Leishmania. J. med. Microbiol., 56: 143-153, 2007. (Pubitemid 46302715)
2. BHATTACHARYYA, A.; MUKHERJEE, M. & DUTTAGUPTA, S. - Studies on stibanate unresponsive isolates of Leishmania donovani . J. Biosci., 27: 503-508, 2002.
3. CHOI, C.M. & LERNER, E.A. - Leishmaniasis: recognition and management with a focus on the immunocompromised patient. Amer. J. clin. Derm., 3: 91-105, 2002.
4. COCHERO, S.; ANAYA, Y.; DIAZ, Y. et al. - Infección natural de Lutzomyia cayennensis cayennensis con parasitos tripanosomatídeos (Kinetoplastida: Trypanosomatidae) en Los Montes de María, Colombia. Rev. cub. Med. trop., 59(1), 2008.
5. DAVIDSON, R.N. - Leishmaniasis. In COHEN, J. & POWDERLY, W.G., ed. Infectious diseases. 2. ed. Edinburgh, Mosby, 2004. Chapter 172.
6. FADILI, K.; MESSIER, N.; LEPROHON, P. et al. - Role of the ABC transporter MRPA (PGPA) in antimony resistance in Leishmania infantum axenic and intracellular amastigortes. Antimicrob. Agents Chemother., 49: 1988-1993, 2005.
7. GENARO, O.; TOLEDO, V.P.C.P.; DA COSTA, C.A. et al. - Vaccine for prophylaxis and immunotherapy, Brazil. Clin. Derm., 14: 503-512, 1996.
8. GONZALEZ, C.; CABRERA, O.L.; MUNSTERMANN, L.E. & FERRO, C. - Distribution of Leishmania infantum vector species in Colombia. Biomédica (Bogotá), 26(suppl. 1): 64-72, 2006.
9. GORE, N. & NICHOLLS, R. - Editorial: Leishmaniasis un reto para la salud publica que exige concertación de voluntades y esfuerzos. Biomédica (Bogotá), 26 (suppl.1), 2006.
10. INFORME DE ACTIVIDADES 2006-2007 AL CONGRESO DE LA REPÚBLICA. Bogotá, 2007. www.minproteccionsocial.gov.co.
11. MAYRINK, W.; CARVALHO-BOTELHO, A.C.; ARAÚJO, P.A. et al. - Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment. Rev. Soc. bras. Med. trop., 39: 14-21, 2006.
12. MURRAY, H.W. - Treatment of visceral leishmaniasis in 2004. Amer. J. trop. Med. Hyg., 71: 787-794, 2004.
13. MURRAY, H.W.; BERMAN, J.D.; DAVIES, C.R. & SARAVIA, N.G. - Advances in leishmaniasis. Lancet, 366: 1561-1577, 2005.
14. OLLIARIO, P.L.; GUERIN, P.J.; GERSTI, S. et al. - Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet infect. Dis., 5: 763-764, 2005.
15. ORGANIZACIÓN MUNDIAL DE LA SALUD (OMS) - Lucha contra la leishmaniosis. Serie de informes técnicos [online]. Ginebra, OMS, 1996. http://www.paho.org/Spanish/AD/DPC/CD/leishmaniasis-manual.htm#nota (accessed 28 April 2008).
16. ORGANIZACIÓN PANAMERICANA DE LA SALUD - Guía para el tratamiento de las enfermedades infecciosas. Washington, OPS, 2004. http://www.ops-oms.org/common/Display.asp?Lang=S&RecID=9629
17. PEARSON, R.D.; QUEIROZ, A. & JERONIMO, S.M.B. - Leishmania species: visceral (Kala-Azar), cutaneous, and mucocutaneous leishmaniasis. In: MANDEL, G.L.; BENNETT, J.E. & DOLIN, R., ed. Principles and practice of infectious diseases. New York, Elsevier/Churchill Livingstone, 2005. v.2, chapter 273.
18. PINTADO, V. & LÓPEZ-VÉLEZ, R. - Visceral leishmaniasis associated with human immunodeficiency virus infection. Enferm. infecc. Microbiol. clin., 19: 353-357, 2001. (Pubitemid 32952996)
19. ROSENTHAL, E.; MARTY, P.; POIZOT-MARTIN, I. et al. - Visceral leishmaniasis and HIV-1 co-infection in southern France. Trans. roy. Soc. trop. Med. Hyg., 89: 159-162, 1995.
20. SINGH, N. - Drug resistance mechanisms in clinical isolates of Leishmania donovani. Indian J. med. Res. 123: 411-422, 2006.
21. SOTO, J. & SOTO, P. - Estado actual y futuro de la terapia antileishmania en Colombia. Biomédica (Bogotá), 26(suppl. 1): 194-206, 2006.
22. SUNDAR, S.; JHA, T.K.; THAKUR, C.P. et al. - Low-dose liposomal Amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Amer. J. trop. Med. Hyg., 66: 143-146, 2002.
23. SUNDAR, S.; JHA, T.K.; THAKUR, C.P. et al. - Oral miltefosine for Indian visceral leishmaniasis. New Engl. J. Med., 347: 1739-1746, 2002. (Pubitemid 35375612)
24. SUNDAR, S. & KUMAR, A. - Challenges in the management of visceral leishmaniasis. Indian Pediat., 42: 523-526, 2005.
25. SUNDAR, S. & CHATTERJEE, M. - Visceral leishmaniasis: current therapeutic modalities. Indian J. med. Res.,123: 345-352, 2006.
26. SUNDAR, S.; JHA, T.K.; THAKUR, C.P.; SINHA, P.K. & BHATTACHARYA, S.K. - Injectable paromomycin for visceral leishmaniasis in India. New Engl. J. Med., 356: 2571-2581, 2007. (Pubitemid 46961002)
27. THAKUR ,C.P.; MITRA, D.K. & NARAYAN, S. - Skewing of cytokine profiles towards T helper cell type 2 response in visceral leishmaniasis patients unresponsive to sodium antimony gluconate. Trans. roy. Soc. trop. Med. Hyg., 97: 409-412, 2003.
28. TOLEDO, V.P.C.P.; MAYRINK, W.; GOLLOB, K.J. et al. - Immunochemotherapy in American cutaneous leishmaniasis: immunological aspects before and after treatment. Mem. Inst. Oswaldo Cruz, 96: 89-98, 2001.
29. UNDP/World Bank/WHO - Special programme for research and training in tropical diseases. Tropical diseases research: progress 2005-2006. Highlights 2005-06. Geneva, World Health Organization. http://www.who.int/tdr/publications/ publications/pr18.htm 2005-2006 (Accessed May 5, 2008).
30. VELEZ, I.D.; AGUDELO, S.; HENDRICKX, E. et al. - Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized controlled trial. Ann. intern. Med., 126: 232-236, 1997.
31. VELEZ, I.D.; HENDRICKX, E.; ROBLEDO, S.M. & DEL PILAR AGUDELO, S. - Leishmaniosis cutánea en Colombia y género. Cadern. Saúde públ. (Rio de J.), 17: 171-180, 2001.
32. VELEZ, I.D.; GILCHRIST, K.; ARBELAEZ, M.P. et al. - Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia. Trans. roy. Soc. trop. Med. Hyg., 99: 593-598, 2005.